Cherwell improves support for pharmaceutical microbiology in Republic of Ireland
Redipor Prepared Media from Cherwell Laboratories
Redipor prepared media to be supplied directly to customers.
Cherwell Laboratories will now be delivering their Redipor prepared media directly to customers in the Republic of Ireland. Cherwell are renowned for offering a flexible supply of quality prepared microbiological media products, and this development will now enable Cherwell to offer improved service and support to customers in the Republic of Ireland.
Since some of the leading international names in the pharmaceutical industry operate manufacturing sites in Ireland, Cherwell recognises the importance of this market for environmental monitoring, product sterility testing, as well as operator and process validation. Andy Whittard, Managing Director, Cherwell Laboratories commented: “Our recent investment in resources and expertise within the company now allows us to focus on regions where our Redipor product is not established. By developing closer relationship with customers it will allow us to ensure we deliver the best prepared media solutions and dedicated customer service.” Cherwell will now ship Redipor product directly from their UK manufacturing facility in Oxfordshire to customers in the Republic of Ireland.
To further enhance their customer service and support in that region, Cherwell are also currently recruiting for a Sales Specialist, based in the Republic of Ireland. Cherwell Laboratories’ Sales Manager, Andrew Barrow remarked: “While we pride ourselves on the customer service we provide by phone and email, we appreciate the importance of having support locally that customers can contact. Fulfilling this new role will help us to build and maintain links with customers, allowing us to fully understand and satisfy their needs.” Cherwell will continue to work with their distributor in Belfast, Davidson & Hardy, for the supply of Redipor products in Northern Ireland.
Further demonstrating their commitment to the Irish market, Cherwell have also recently become a corporate member of the Irish Cleanroom Society. The society provides a forum for the exchange of ideas and working practices, a support network and works closely with the Cleanroom Testing and Certification Board to run a series of training courses.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...